Nanomedicine for targeting the lung cancer cells by interpreting the signaling pathways

被引:12
作者
Habeeb, Mohammad [1 ]
Kareem, Tasneem Abdul [2 ]
Deepthi, Kolluru Lakshmi [3 ]
Khot, Vidyarani Sujitkumar [4 ]
Woon, You Huay [5 ]
Pawar, Sarita Suryabhan [6 ]
机构
[1] BS Abdur Rahman Crescent Inst Sci & Technol, Crescent Sch Pharm, Dept Pharmaceut, Chennai 600048, India
[2] SRM Inst Sci & Technol, SRM Coll Pharm, Dept Pharm Practice, Kattankulathur 603203, India
[3] Sri Sai Coll Pharm, Dept Pharmaceut, Vijayanagaram 535270, Andhra Pradesh, India
[4] Sanjay Ghodawat Univ, Sch Pharmaceut Sci, Dept Pharmacol, Kolhapur 416118, India
[5] Univ Kebangsaan Malaysia, Pusat GENIUSPintar Negara, Bangi 43600, Selangor, Malaysia
[6] Sanjivani Coll Pharmaceut Educ & Res, Dept Pharmaceut Chem, Ahmednagar 423603, India
关键词
Lung cancer; Toxicity; Cell signaling; Nanocarriers; Drug delivery; DRUG-DELIVERY; DOXORUBICIN NANOPARTICLES; OXIDE NANOPARTICLES; SUPPRESSOR-CELLS; OPEN-LABEL; IN-VITRO; RECEPTOR; THERAPY; GUIDELINES; EXPRESSION;
D O I
10.1016/j.jddst.2022.103865
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lung malignancy is one of the prominent causes of cancer death worldwide. However, the treatment and diagnosis of various lung cancer becoming increasingly challenging. Currently, several types of treatments and/ or diagnostic methods are used to treat lung diseases. One of the reasons for the higher mortality was the uptake of anticancer agents by normal cells. Lung cancer has complicated pathogenesis that includes multiple signaling pathways that can be used to target malignant cells. Onco-receptors such as epidermal growth factor (EGFR) receptor, integrins, transferrin (TFR) receptor, folate receptor (FR), and the cluster of differentiation 44 (CD44) receptors are augmented on the surface proteins of malignant cells, and many other receptors may be exploited for the inhibition of pathways. Further cancer-borne immunological targets may assist as a marked spot to regulate cell-specific pathways. Nanotechnology has been intensively investigated in healthcare as technological advancement. Multiple nano-based systems are employed to improve lung cancer identification methods and treatment efficacy when compared to standard delivery methods. To resolve complex lung barriers and boost the therapeutic effect while limiting systemic side effects, nanoparticles are transported to the lungs, appropriate therapeutic medicines are loaded, and intelligent functionalities are incorporated. This article gives the various signaling pathways to target lung malignant and also the development of the latest nanotechnology drug distribution stratagems in recent years and studies the medical application worth of nanomedicine for the treatment of lung cancer.
引用
收藏
页数:16
相关论文
共 50 条
[41]   Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer [J].
Haider, Mohamed ;
Elsherbeny, Amr ;
Pittala, Valeria ;
Consoli, Valeria ;
Alghamdi, Maha Ali ;
Hussain, Zahid ;
Khoder, Ghalia ;
Greish, Khaled .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
[42]   Multimodal Nanomedicine Strategies for Targeting Cancer Cells as well as Cancer Stem Cell Signalling Mechanisms [J].
Kanwar, Jagat R. ;
Samarasinghe, Rasika M. ;
Kamalapuram, Sishir K. ;
Kanwar, Rupinder K. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2017, 17 (18) :1688-1695
[43]   Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer [J].
Wathoni, Nasrul ;
Puluhulawa, Lisa Efriani ;
Joni, I. Made ;
Muchtaridi, Muchtaridi ;
Mohammed, Ahmed Fouad Abdelwahab ;
Elamin, Khaled M. ;
Milanda, Tiana ;
Gozali, Dolih .
DRUG DELIVERY, 2022, 29 (01) :2959-2970
[44]   Targeting molecular signaling pathways of Schistosoma haematobium infection in bladder cancer [J].
Botelho, Monica Catarina ;
Machado, Jose Carlos ;
Brindley, Paul J. ;
Correia da Costa, Jose Manuel .
VIRULENCE, 2011, 2 (04) :267-279
[45]   Lung cancer nanomedicine: potentials and pitfalls [J].
Boeluekbas, Deniz Ali ;
Meiners, Silke .
NANOMEDICINE, 2015, 10 (21) :3203-3212
[46]   Autophagy-related signaling pathways in non-small cell lung cancer [J].
Wang, Jing ;
Gong, Mei ;
Fan, Xirong ;
Huang, Dalu ;
Zhang, Jinshu ;
Huang, Cheng .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2022, 477 (02) :385-393
[47]   Nanomedicine-mediated drug targeting of cancer stem cells [J].
Singh, Deepika ;
Minz, Aliva Prity ;
Sahoo, Sanjeeb Kumar .
DRUG DISCOVERY TODAY, 2017, 22 (06) :952-959
[48]   Targeting lipid metabolism via nanomedicine: A prospective strategy for cancer therapy [J].
Huang, Xing ;
Hou, Shengzhong ;
Li, Yinggang ;
Xu, Gang ;
Xia, Ning ;
Duan, Zhenyu ;
Luo, Kui ;
Tian, Bole .
BIOMATERIALS, 2025, 317
[49]   Unravelling key signaling pathways for the therapeutic targeting of non-small cell lung cancer [J].
Chavan, Pavan Ramrao ;
Pandey, Ruchi ;
Patil, Baswant Malesh ;
Murti, Krishna ;
Kumar, Nitesh .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2025, 998
[50]   Cationic versus anionic core-shell nanogels for transport of cisplatin to lung cancer cells [J].
Gonzalez-Urias, Alejandra ;
Zapata-Gonzalez, Ivan ;
Licea-Claverie, Angel ;
Licea-Navarr, Alexei F. ;
Bernaldez-Sarabi, Johanna ;
Cervantes-Luevano, Karla .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2019, 182